Sort
172,184 grants matching “inflammation”
Mechanisms and biological consequences of the nuclear receptor CAR activation
$2,684,642Masahiko Negishi · National Institute Of Environmental Health Sciences · ZIA · FY2018 · ES
Role of Immune Mechanisms in Athersclerosis and Inflammation
$2,684,515Joseph L Witztum · University Of California, San Diego · P01 · FY2017 · HL
Role of Immune Mechanisms in Athersclerosis and Inflammation
$2,684,515Joseph L Witztum · University Of California, San Diego · P01 · FY2016 · HL
Role of Immune Mechanisms in Athersclerosis and Inflammation
$2,684,515Joseph L Witztum · University Of California, San Diego · P01 · FY2018 · HL
Early Life Adversity, Biological Embedding, and Risk for Developmental Precursors of Mental Disorders
$2,684,011Joan L Luby · Washington University · R01 · FY2025 · MH
Barrier Damage and The Immune CascadeNorthwestern University CounterACT Center of Excellence (NUCCX)
$2,683,799Kurt Lu · Northwestern University At Chicago · U54 · FY2023 · AR
Pathogenesis, and Outcome of Autoinflammatory Diseases, NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still's-like Diseases, and other Undifferentiated Autoinflammatory Diseases
$2,682,681Raphaela Goldbach-Mansky · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Comprehensively Defining the Novel Alphaviral Capsid Protein / IRAK1 Interaction
$2,681,840Kevin Joseph Sokoloski · University Of Louisville · R01 · FY2025 · AI
Innate and Adaptive Immunity in Experimental and Human Gonoccocal Infection
$2,681,405Peter A. Rice · Univ Of Massachusetts Med Sch Worcester · U19 · FY2009 · AI
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
$2,680,709Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2022 · AG
Chemoprophylaxis for HIV Prevention in Men
$2,680,398Robert M. Grant · J. David Gladstone Institutes · U01 · FY2007 · AI
The Inflammatory Index as a Biomarker for Pain in Patients with Sickle Cell Disease
$2,679,842Amanda M Brandow · Medical College Of Wisconsin · R61 · FY2019 · NS
Center for the Study of Immune Mechanisms of Flavivirus Control
$2,679,477Michael J Gale · University Of Washington · U19 · FY2016 · AI
Clarifying the Optimal Application of SLT Therapy (COAST) Trial
$2,679,188Stephen R Wisniewski · University Of Pittsburgh At Pittsburgh · UG1 · FY2022 · EY
Learning from Remission and Relapse in SLE
$2,678,601Betty Diamond · Feinstein Institute For Medical Research · P01 · FY2025 · AI
Protein Glycosylation in the Coagulopathy and Inflammation of Sepsis
$2,677,013Jamey Marth · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2022 · HL
Models and Gene Therapies for AAT Deficiency
$2,676,698Terence R. Flotte · Univ Of Massachusetts Med Sch Worcester · P01 · FY2022 · HL
Allergic sensitization through the airway
$2,676,688Donald N Cook · National Institute Of Environmental Health Sciences · ZIA · FY2024 · ES
Protein Glycosylation in the Coagulopathy and Inflammation of Sepsis
$2,676,393Jamey Marth · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2023 · HL
CLOSED LOOP SACRAL NERVE STIMULATION FOR INFLAMMATION
$2,676,058The Johns Hopkins University · · FY2015 · Department of the Navy
Sirtuins and nuclear receptors in aging and age-associated diseases
$2,675,793Xiaoling Li · National Institute Of Environmental Health Sciences · ZIA · FY2017 · ES
Protein Glycosylation in the Coagulopathy and Inflammation of Sepsis
$2,674,150Jamey Marth · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2025 · HL
Asthma Inflammation Research (AIR)
$2,673,763Serpil C. Erzurum · Cleveland Clinic Lerner Com-Cwru · P01 · FY2012 · HL
Asthma Inflammation Research (AIR)
$2,673,763Serpil C. Erzurum · Cleveland Clinic Lerner Com-Cwru · P01 · FY2011 · HL
Models and Gene Therapies for AAT Deficiency
$2,673,457Terence R. Flotte · Univ Of Massachusetts Med Sch Worcester · P01 · FY2024 · HL